Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07538570
Active, not recruiting Phase 4

Evaluation of Pain Treatment After Total Knee Arthroplasty

NCT07538570 · tracked via the Priya Life Science USA tracker
Sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 4
Started
2026-04-24
Last updated
2026-10-28

Condition(s) studied

Pain

Investigational drug(s) / intervention(s)

Suzetrigine →Placebo

Suzetrigine: Tablets for oral administration.

Placebo: Placebo matched to SUZ for oral administration

Study summary

The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Key Inclusion Criteria: * Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2) * Scheduled to undergo an elective primary unilateral TKA surgery Key Exclusion Criteria: \- History of previous TKA surgery on incident side Other protocol defined Inclusion/Exclusion criteria will apply.

Primary outcome measure(s)

  • Total Opioid Usage — 24 hours to 168 hours after the first dose of study drug

Trial sites (2)

FacilityCityRegionStatus
Legent Orthopedic and Spine Hospital Bellaire Texas
Memorial Hermann Village Office Houston Texas

More Vertex Pharmaceuticals Incorporated trials in the USA

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy Active, not recruiting
Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older Enrolling by invitation
A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes Recruiting
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis Active, not recruiting
A Long-term Follow-up Study in Participants Who Received CTX001 Enrolling by invitation

Other trials for the same condition

An Open-Label, Safety and Efficacy Study of Cebranopadol in Participants With Acute Pain With Surgical or Non-Surgical Origin Recruiting
RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain Recruiting
Phase 1 Study of SBS-147 in Healthy Adults Recruiting
RHA® Redensity With New Anesthetic Agent Perioral Rhytids (PAS) Active, not recruiting
Registry of Outcomes of Dezawa MuseCells® Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07538570 on ClinicalTrials.gov ↗ ← All trials in the USA